Iron oxide nanoparticles

Phase 2Small molecule

Iron oxide nanoparticles is one of 6 small molecule programs targeting Rectal Cancer Patients. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal Cancer PatientsRecruiting

Rectal Cancer PatientsPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Rectal Cancer Patients

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

1 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

3 3

Mfolfox6

Roche

Phase 2

1 4

PD-1 Blocking Antibody

SSun Yat-sen University

Phase 1

1 5

Iron oxide nanoparticles

NNanoEcho AB

Phase 2

1 6

CAPOX Chemotherapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rectal Cancer Patients1 trial

To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.

Recruiting·NNanoEcho AB·Phase 2·NCT06693375·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iron oxide nanoparticles. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron oxide nanoparticles compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron oxide nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NanoEcho AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNanoEcho AB

Iron oxide nanoparticles

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rectal Cancer Patients1 trial

References

Drug Info

Quick Facts

Related News